Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07286149 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
A Phase 1 study of Lung Neoplasm Malignant, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 190
- Enrollment target
- 3
- Study locations
NCT07286149: Recruiting Phase 1 study of Lung Neoplasm Malignant, sponsored by Merck Sharp & Dohme.
NCT07286149 is a Phase 1 study of Lung Neoplasm Malignant that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 190 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (217% higher). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07286149, a Phase 1 study of Lung Neoplasm Malignant, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 190 participants
- Enrollment target
- 3
- Study locations
Study Summary
Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn: * About the safety of MK-1084 and if people tolerate it when taken with other treatments * How many people have the cancer respond (get smaller or go away) to the treatments
Primary Outcome
DLT will be defined as any drug-related AE observed during the DLT evaluation period (up to 42 days) that results in a change to a given dose or a delay in initiating the next treatment.
Conditions Studied
Interventions
- BIOLOGICAL Sacituzumab tirumotecan
- BIOLOGICAL Cetuximab
- DRUG Rescue Medications
- BIOLOGICAL Patritumab deruxtecan
- DRUG MK-1084
Study Locations (3)
Other
- Shaare Zedek Medical Center ( Site 0186) - Jerusalem
- Severance Hospital, Yonsei University Health System ( Site 0080) - Seoul
Florida
- Clermont Oncology Center ( Site 0041) - Clermont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2026-03-23 |
| Est. Completion | 2037-05-06 |
| Phase | Phase 1 |
What NCT07286149 shows while recruiting
NCT07286149 is an interventional study that assigns participants to a tested intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (217% higher).
The record links to 1 condition, with Lung Neoplasm Malignant appearing as the primary indexed condition, and to 5 interventions - of which Sacituzumab tirumotecan is the first listed.
NCT07286149 reports a single indexed study location in Other, Florida.
Frequently Asked Questions
What is clinical trial NCT07286149 about?
NCT07286149 is a clinical study titled "A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)". Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn: * About the safety of MK...
What is the current status of trial NCT07286149?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 190 participants. The study started on 2026-03-23. Estimated completion is 2037-05-06.
What conditions does trial NCT07286149 study?
This clinical trial studies the following conditions: Lung Neoplasm Malignant.
What interventions are being tested in trial NCT07286149?
The interventions under investigation include: Sacituzumab tirumotecan (BIOLOGICAL), Cetuximab (BIOLOGICAL), Rescue Medications (DRUG), Patritumab deruxtecan (BIOLOGICAL), MK-1084 (DRUG).
Who is sponsoring clinical trial NCT07286149?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07286149 being conducted?
This trial has 3 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Neoplasm Malignant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07286149's enrollment target sits among peer trials
190 285th of 2000 higher than 1,713 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03257033 · 190 participants · Phase 3
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- NCT03642028 · 190 participants · Phase 4
Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
- NCT04015609 · 190 participants · NA
Psychotherapy Intervention for Latinos With Advanced Cancer
- NCT04284397 · 190 participants · Early Phase 1
Identification of Critical Thermal Environments for Aged Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI